Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > REGULATORY
REGULATORY
- MHLW Adds Six APIs/10 Products Including Tenelia to NHI Price List
August 29, 2012
- PMDA Eyes World’s First Approval for New Drugs: Chief Executive Kondo
August 28, 2012
- Drug-Dispensing Expenditure Rises 7.9% to 6,513.3 Billion Yen in FY2011: MHLW
August 28, 2012
- PAFSC 2nd Committee to Review 5 Products Including Novartis’s COPD Drug on Sept. 6
August 24, 2012
- Domestic Pharmaceutical Production Up 3.1 %, to Record high 6,987.4 Bil. Yen in 2011
August 24, 2012
- Two Healthcare Provider Reps at CSIMC Criticize Marketing of a Single Drug under Different Brand Names as “Undesirable”
August 24, 2012
- CSIMC Expert Subcommittee Favors Single Index for Efficacy Assessment of Medical Technology
August 24, 2012
- Drug Pricing Subcommittee Presents Negative Views on Reference Pricing System; “Concerns over Patient Copayment Increases”
August 24, 2012
- MHLW to Recommend Use of ReQuip CR Tablets
August 23, 2012
- CSIMC Approves Listing for 6 APIs/10 Products; Peak Sales Projected at 45.6 Billion Yen for Tenelia
August 23, 2012
- Nonpartisan League of Diet Members Aims to Submit Bill during Current Diet Session to Promote Measures against Strokes
August 23, 2012
- Introduction of RMPs Will Enable Clearer Strategies for Post-Marketing Safety: Ms Tawaragi of PFSB
August 23, 2012
- MHLW Budget Request to Focus on Life Innovation: Minister Komiyama
August 22, 2012
- PMDA’s Regulatory Consultation Service Off to Good Start, but More Effort Needed to Promote Face-to-Face Advisory Meetings: Dr Isobe
August 22, 2012
- Healthcare to Receive Priority in FY2013 Draft Budget Request Guidelines
August 21, 2012
- PAFSC’s 1st Committee to Review 7 Products Including Bayer Yakuhin’s AMD Drug on Aug. 31
August 20, 2012
- Subcommittee on Refractory Diseases Prepares to Improve Medical Expenditure Subsidies: Interim Report
August 20, 2012
- PMDA Meets Targets for FY2011, but Measures Needed to Reduce Applicants’ Processing Time: MHLW’s Evaluation Council
August 20, 2012
- MHLW Designates 4 Products Including Thyroid Cancer Agent as Orphan Drugs
August 20, 2012
- US Regulation Could Delay Introduction of PBRER as ICH Standard
August 17, 2012
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…